Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd

Company Profile

• Business description

  Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd formerly, Hangzhou Jiuyuan Gene Engineering Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, It has built a diversified product portfolio comprising eight marketed products, including China’s first recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair material, Guyoudao, and over ten product candidates, including the first semaglutide biosimilar in China to have obtained an IND approval and filed an NDA, JY29-2.

• Contact

  No. 23, Eighth Street Baiyang Street
  Qiantang District
  Zhejiang Province
  Hangzhou
  CHN

  T: +86 57186910099

  https://www.china-gene.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  1,541